2,2-dimethylbutyric acid has been researched along with Hemoglobinopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chui, DH; Dai, Y; Faller, DV; Fucharoen, S; Luo, HY; Perrine, SP; Sangerman, J | 1 |
| Bashirov, R; Mehraei, M; Tüzmen, Ş | 1 |
2 other study(ies) available for 2,2-dimethylbutyric acid and Hemoglobinopathies
| Article | Year |
|---|---|
Therapeutic fetal-globin inducers reduce transcriptional repression in hemoglobinopathy erythroid progenitors through distinct mechanisms.
Topics: Benserazide; Butyrates; Cell Line; Chromatin Immunoprecipitation; Erythroid Precursor Cells; gamma-Globins; Hemoglobinopathies; Histone Deacetylase Inhibitors; Humans; RNA, Messenger; Transcriptional Activation | 2016 |
Target-based drug discovery for [Formula: see text]-globin disorders: drug target prediction using quantitative modeling with hybrid functional Petri nets.
Topics: Adult; Aminopyridines; Benzamides; beta-Globins; Butyrates; Carrier Proteins; Drug Discovery; Fetal Hemoglobin; gamma-Globins; Hemoglobinopathies; Histone Deacetylase 1; Humans; Hydroquinones; Kruppel-Like Transcription Factors; Models, Theoretical; Molecular Targeted Therapy; Nuclear Proteins; Pyridines; Quinolines; Repressor Proteins; Simvastatin; SOXD Transcription Factors | 2016 |